Search PubMed⌕ Search

Biomedical subjects

G Glaeske

Publications and source records attributed to G Glaeske.

17 recordsLinked to original sources
PubMed1999

[Evidence-based medicine from the point of view of health insurance companies--a frame for qualified freedom of therapy and an improved economy?].

The rationality and efficiency of medical care must be improved from the point of view of the statutory health insurance system in Germany. Too many diagnostic and therapeutic procedures are of doubtful usefulness, the high amount of many procedures is unnecessary. 10% of all expenditures in the health care sector or around 25 billion DM could probably be saved if evidence based guidelines are taken as a basis for decisions in medical care. Evidence based medicine not only improves the efficiency, but supports also the therapeutic freedom of the physicians in limiting the vagueness of many medical decisions. EBM is therefore a strategy of the sick fund systems that supports the quality and efficiency of the medical care for the insured people.

Costs and Cost Analysis↗
PubMed1994

Quality control of drug prescriptions by positive lists--the European Formulary.

The overall quality of drug prescription is based on three elements: structural, procedural and result quality. In order to improve the clinical outcome (= result quality) of a patient, only drugs with a proven efficacy and a well known risk/benefit-relation should be prescribed. However, in 1992 in Germany, 31.1% of the ambulatory drug prescriptions were for drugs with questionable efficacy or dubious combination preparations. These expenditures therefore cannot be justified, neither from a pharmacological point of view nor from an economic standpoint. One of the main reasons for this poor prescribing quality is a poor structural quality, i.e. too many drugs and lack of transparency on the market and a producer-oriented drug information. In order to improve this structural quality, a drug list will be established by a group of 33 pharmacologists, physicians and pharmacists from 15 European countries. This list aims at 66 diseases, which are thought to be the most common for the general practitioners everyday routine. For these illnesses drug therapies are recommended including information on drug side-effects, possible interactions and contra-indications. Furthermore, basing on published literature, all possible drugs for the 66 indications will be discussed explaining and underlining the choice of the European Formulary Group. However, even a comprehensive drug list may not rule out insufficient procedural quality, i.e. too lengthy prescriptions of benzodiazepines, but may hopefully facilitate the rational choice of drugs and therefore improve patients outcome.

Drug Evaluation↗
PubMed1994

[Do legal regulations obstruct adequate quality assurance in the area of drug therapy?].

In Germany the quality of drug therapy suffers from the lack of transparency of an overloaded drug market, from the turnover-oriented information strategies of the pharmaceutical industry and from the lack of prescribing transparency and quality control of the individual doctor. After an analysis of the present deficient situation in the area of drug therapy the following paper discusses strategies to improve structure as well as process quality. It also stresses the necessity of implementing a legal framework to analyse individual patients' records aimed at controlling the quality of therapy. Because of problems with confidentiality continuous patient record linking is not allowed although it is a precondition for an adequate control of the patients progress and the quality of results.

Drug Industry↗
PubMed1987

[Analgesic consumption in the Federal Republic of Germany. The extent and the risk groups].

An analysis of still unpublished sales statistics shows that during 1976-1983 the annual sales of all analgesic package units remained relatively stable (about 115 million units per year), while the consumption of large packings mostly preferred by analgesic abusers increased from 8.13 to 11.28 million (units of 100 tablets). The annual per capita consumption of analgesic substances (1983) was 18.2 g. Among these, drugs containing salicylate and phenazone headed the list, whereas phenacetin consumption is increasingly on the downgrade (0.87 g per capita). 95% of all analgesics are used outside of the clinics. Furthermore, 80% of them are purchased on the prescription-free market. High consumption of analgesics can be assumed in 5% of the normal population. Analgesic abuse is more prevalent in women, especially in some industrial areas.

Analgesics↗
PubMed1986

The analgesic problem in the Federal Republic of Germany: analgesic consumption, frequency of analgesic nephropathy and regional differences.

The recent withdrawal of phenacetin from the pharmaceutical market in the FRG has stimulated the discussion of the extent of analgesic abuse and analgesic nephropathy (AN). Data from wholesale statistics, given here, revealed in the FRG population a high yearly per-capita consumption of analgesics (18.2 g), mostly used in mixed compounds. According to standardized data, the FRG ranks first among the north European countries. We suggest that the prevalence data given from the EDTA-registry (4.6% of the endstage renal population) underestimates the real extent of AN. AN in the FRG shows a north-to-south decline and is most prevalent in northern areas and West Berlin. It is assumed that the analgesic dilemma in the FRG is identical to the dilemma in Switzerland and Belgium.

Adolescent↗